Your browser doesn't support javascript.
loading
Etiologies of Persistent Aminotransferase Elevations in Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogs.
Xiong, Qing-Fang; Zou, Lei; Chen, Zi-Jie; Liu, Hong-Li; Lu, Yu-Jia; Liu, Du-Xian; Yang, Yong-Feng.
Afiliación
  • Xiong QF; Department of Liver Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China.
  • Zou L; The Clinical Infectious Disease Center of Nanjing, Nanjing, China
  • Chen ZJ; Department of Liver Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China.
  • Liu HL; The Clinical Infectious Disease Center of Nanjing, Nanjing, China
  • Lu YJ; Department of Clinical Medicine, Hubei University of Science and Technology, Xianning, China
  • Liu DX; Southeast University School of Medicine, Nanjing, China
  • Yang YF; Department of Liver Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China.
Turk J Gastroenterol ; 35(6): 497-504, 2024 02 29.
Article en En | MEDLINE | ID: mdl-39101697
ABSTRACT
Background/

Aims:

Recent studies revealed that patients with persistent aminotransferase elevations after antiviral treatment had higher risk of hepatic events; yet its underlying causes remain unclear. Our study aimed to investigate the etiologies of persistent aminotransferase elevations in patients treated with nucleos(t)ide analogs (NAs). Materials and

Methods:

A retrospective study was conducted on chronic hepatitis B (CHB) patients who had been receiving NA treatment for over a year and had an aminotransferase level greater than 40 IU/mL (more than twice, with a 3-month interval) and subsequently underwent a liver biopsy.

Results:

The study group included 46 patients (34 males) with a mean age of 44.8 ± 20.3 years (range 24-71 years).The average dura- tion of NA therapy was 3.7 years (1.1-10.6 years). The etiologies of persistant transaminase elevation were categorized into 4 groups patients with low hepatitis B virus (HBV) viral load (LVL, n = 11); concurrent non-alcoholic fatty liver disease (NAFLD, n = 12); concurrent other liver diseases (OLD, n = 12); and unknown liver dysfunction (ULD, n = 11). The proportion of G ≥ 2 inflammation was significantly higher in the LVL group (90.9%) compared to NAFLD (33.3%), OLD (50%), and ULD (27.2%) groups (P = .012). The hepatitis B e-antigen (HBeAg)-positive group exhibited a younger age (34.5 ± 10.2 vs. 48.1 ± 9.4 years, P < .001), a lower proportion of fibrosis F ≥ 2 (36.3% vs. 77.1%, P = .012), and a higher prevalence of detectable HBV DNA (54.5% vs.14.2%, P = .00632) compared to the HBeAg-negative group.

Conclusion:

The etiology of persistent aminotransferase elevations in CHB patients undergoing NAs treatment warrants investigation. Besides the commonly observed NAFLD and low HBV viral load, concurrent presence of other liver diseases requires elucidation.The proportion of G≥2 inflammation was higher in the LVL group.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Carga Viral / Hepatitis B Crónica / Alanina Transaminasa Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Turk J Gastroenterol Asunto de la revista: GASTROENTEROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Turquía
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Carga Viral / Hepatitis B Crónica / Alanina Transaminasa Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Turk J Gastroenterol Asunto de la revista: GASTROENTEROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Turquía